지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Purpose: The purpose of this study is to evaluate current criteria for insurance coverage by Health Insurance Review &Assessment Service (HIRA) on the systemic therapy used in the treatment of advanced or metastatic renal cell carcinoma (RCC), by reviewing all available clinical evidences including a variety of clinical practice guidelines.
Methods:We searched clinical databases and collected data from published phase 1 through 3 randomized clinical trials on all systemic therapies used in RCC, including novel targeted therapies. Additionally, current clinical practice guidelines on the management of kidney cancer or RCC were reviewed. Based on the collected data we evaluated the appropriateness of the HIRA criteria for insurance coverage on the systemic therapy of RCC whether they are evidence-based and up to date.
Results: On the basis of the collected data we concluded that there was a need for a revision in HIRA criteria for systemic therapy of RCC. Despite recent emerging therapeutic advances and changes in therapeutic strategies of management of RCC, some of anticancer regimens were inappropriately listed even though they were not proven to provide efficacy or safety superior to those of other therapies. We thus proposed an updated recommendation based on current clinical evidences.
Conclusion: Systemic therapy of RCC is being rapidly changed with the advancement of understanding of the molecular biology of cancer. Consequently newly developed targeted therapies are becoming the standard therapy in the management of medically or surgically unresectable advanced or metastatic RCC. To provide effective and safe therapy to patients with RCC, the criteria for insurance coverage should be made carefully taking into consideration of most up-todate and high-quality clinical evidences, and should be continuously reviewed so as to reflect evidence-based clinical practice.
목차
등록된 정보가 없습니다.
참고문헌 (27)
참고문헌 신청
/ / 보건복지부-국립암센터 국가암정보센터 암정보서비스 신 장암의 관련 통계
Board RE / 2007 / Anti-angiogenic therapy in the treatment of advanced renal cell cancer / Cancer Treat Rev 33 : 1 ~ 8
Chouhan JD / 2007 / Sunitinib (Sutent®): A novel agent for the treatment of metastatic renal cell carcinoma / J Oncol Pharm Practice 13 : 5 ~ 16
Coppin C / 2005 / Immunotherapy for advanced renal cell cancer / Cochrane Database Syst Rev 1 : CD001425 ~
Corgna E / 2007 / Renal cancer / Crit Rev Oncol Hematol 64 : 247 ~ 262
Board RE / 2007 / Anti-angiogenic therapy in the treatment of advanced renal cell cancer / Cancer Treat Rev 33 : 1 ~ 8
Chouhan JD / 2007 / Sunitinib (Sutent®): A novel agent for the treatment of metastatic renal cell carcinoma / J Oncol Pharm Practice 13 : 5 ~ 16
Coppin C / 2005 / Immunotherapy for advanced renal cell cancer / Cochrane Database Syst Rev 1 : CD001425 ~
Corgna E / 2007 / Renal cancer / Crit Rev Oncol Hematol 64 : 247 ~ 262
이 논문의 저자 정보
최근 본 자료
댓글(0)
0